News | May 28, 2007

Stentys Presents Outcomes on Bifurcation Device

May 29, 2007 — Stentys says the results of preclinical testing of its bifurcated stent were reported at last week's EuroPCR 2007 Cardiovascular Congress.

Stentys is the first company to develop the next-generation of dedicated drug-eluting stents for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.

"The Stentys device has been successfully evaluated in porcine coronary and renal arteries," said Jean-Claude Laborde, M.D., principal investigator, who is co-director of the interventional cardiology unit at Clinique Pasteur, Toulouse, France, and a member of the Scientific Advisory Board of Stentys. "In addition to determining the most suitable vessel diameters, our study achieved the primary endpoints of acute device success and acute procedure success. The acute device success was graded (0 to 3) for insertion, deployment of the stent and creation of the side branch, with grade 2 being the benchmark.

"The acute procedure success was defined as achieving TIMI (Thrombolysis In Myocardial Infarction) grade-3 flow in the main and side branch following deployment. The device achieved excellent results (87 percent and 92 percent, respectively) in both of the areas evaluated. Optimal apposition of the stent in the main vessel and side branch was confirmed with intravascular ultrasound (IVUS). The results clearly demonstrate that this frangible stent can split only when it is needed, while still offering excellent trackability, positioning and deployment."

The patent-pending innovation of Stentys'bifurcated stent is that the stent-opening for the side branch can be created anywhere in the stent after it is implanted in the vessel. In short, the procedure's success is independent from accurate positioning. The Stentys procedure is performed in three simple steps: (1) Stentys is implanted in the main vessel with an approximate positioning, like a standard stent; (2) the cardiologist chooses the optimal location for the side branch opening by inserting a balloon through the stent mesh, which is a cath lab-standard procedure; and, (3) the balloon inflation disconnects the mesh and creates the opening — the Stentys approach allows the in situ modeling of the stent to fit the patient's unique arterial anatomy.

Based in Paris, Stentys intends to make treatment of blocked coronary artery bifurcations as simple and effective as a regular stenting procedure.

For more information visit www.stentys.com.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init